

OCULISTICA

- Protocollo CRFB002FIT01 -StudioA 12-month, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia.

Sperimentatore principale : **Prof. Enzo Maria Vingolo**

- Protocollo CRFB002AIT02 dal titolo "A 12 months, prospective, multicenter, open-label, single arm interventional study assessing the safety and tolerability of 0.5 mg ranibizumab in mono/bilateral wet AMD patients in eyes with BCVA below 2/10 and/or second affected eye"

Sperimentatore principale : **Prof. Enzo Maria Vingolo**